DexCom Faces New Reports Of Deaths Linked To G7 Glucose Monitor

Core Insights - DexCom Inc is under scrutiny following reports of three deaths linked to its G7 continuous glucose monitor, raising safety concerns about the device [1][4]. - An investigation by Hunterbrook criticized DexCom for failing to ensure the accuracy and reliability of the G7 device, with reports of severe complications among patients [2]. - Class action lawsuits have been filed against DexCom, alleging misleading information regarding the accuracy of its monitoring system [3]. Regulatory and Legal Issues - The FDA's MAUDE database has recorded at least 13 deaths associated with the G7 since its launch in 2023, highlighting ongoing safety issues [5]. - A warning letter was issued to DexCom by the FDA in March 2025, citing potential sensor malfunctions and communication errors [6]. - Legal actions include class action lawsuits and a separate securities lawsuit filed against the company [3]. Market Performance - DexCom's stock has seen a decline, with shares down 2.87% to $68.59 at the time of publication [6].